Linio Biotech Received Investment

Finnish biotech growth company Linio Biotech has announced a new investment round of EUR 4.2 million, bringing the company's total financing to over EUR 9 million. In addition to previous family offices and private investors, Linio Biotech's investors will now include new Finnish private investors and doctors familiar with the sector.

Also See: Kinterra Capital Creates $565 Million New Fund

Linio Biotech's Innovation is an Injectable Tissue Product Called Tience®

Linio Biotech was founded in 2017 as a spin-off of the University of Tampere by co-founders Timo Ylikomi, professor of cell biology, and Riina Uusmies, cell biologist and researcher. It should be noted that Tience® products are manufactured in Tampere, Finland. Linio Biotech's innovation is an injectable tissue product called Tience® (from the words tissue science). The product is intended for professional use only. It helps the skin to regenerate itself naturally by accelerating the natural healing process of the skin. Tience® treatment can be used to repair various skin imperfections such as signs of ageing or unwanted visible scars. Note for the new funding. It will help Linio Biotech to expand the availability of Tience® products and treatments. Tience® was launched in Finland in June 2023. It is also at the beginning of commercialisation in other Nordic countries.